Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Public health policy

2915 - Magnitude of Clinical Benefit of Cancer Drugs Approved Based on Single-Arm Trials (SAT) by the US Food and Drug Administration (FDA)

Date

20 Oct 2018

Session

Poster Discussion session - Public health policy

Topics

Bioethical Principles and GCP

Tumour Site

Presenters

Consolacion Molto Valiente

Citation

Annals of Oncology (2018) 29 (suppl_8): viii562-viii575. 10.1093/annonc/mdy297

Authors

C. Molto Valiente1, M. Borrell2, A. Ocana Fernandez3, A.J. Templeton4, L.P. del Carpio1, J. Del Paggio5, A. Barnadas6, C.M. Booth7, A. Tibau1, E. Amir8

Author affiliations

  • 1 Oncology Department, Hospital de la Santa Creu i Sant Pau and Universitat Autònoma de Barcelona, 8026 - Barcelona/ES
  • 2 Oncology Department, Hospital de la Santa Creu i Sant Pau and Universitat Autònoma de Barcelona, 08041 - Barcelona/ES
  • 3 Medical Oncology Department And Translational Research Unit, Albacete University Hospital, 2006 - Albacete/ES
  • 4 Department Of Medical Oncology, St Claraspital and Faculty of Medicine, University of Basel, 4058 - Basel/CH
  • 5 Division Of Cancer Care And Epidemiology, Queen’s University Cancer Research Institute, Kingston/CA
  • 6 Oncology Department, Hospital de la Santa Creu i Sant Pau and Universitat Autònoma de Barcelona, 08026 - Barcelona/ES
  • 7 Departments Of Oncology And Public Health Sciences, Queen's University, K7L 3N6 - Kingston/CA
  • 8 Division Of Medical Oncology & Hematology, Department Of Medicine, Princess Margaret Cancer Centre and the University of Toronto, M5G2M9 - Toronto/CA
More

Resources

Abstract 2915

Background

The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a validated and reproducible tool to assess the magnitude of clinical benefit from anti-cancer drugs. In contrast to version 1.0 (v1.0) of this tool, which could be used to assess randomized controlled trials (RCT) only, the updated version 1.1 (v1.1) allows scoring of drugs approved on the basis of single-arm trials (SAT). Here, we applied the updated ESMO-MCBS v1.1 to the assessment of trials supporting FDA approval including those based on SAT.

Methods

We searched the Drugs@FDA website for anticancer drug approvals from January 2006 to December 2016. Drug labels and reports of registration trials were reviewed and study characteristics, efficacy, toxicity, and quality of life outcomes as well as regulatory pathways were collected. For RCT, ESMO-MCBS v1.0 and v1.1 grades were applied; for SAT only v1.1 was used. Substantial benefit was defined as a grade of A or B for trials of curative intent and 4 or 5 for those of palliative intent. Agreement between v1.0 and v1.1 scores was assessed using Cohen’s κ statistic.

Results

Of 134 studies supporting FDA approval, 4 reported preplanned analyses in multiple subgroups but in 5, ESMO-MCBS could not be applied. Therefore, analysis was based on 133 data points. Of these, only 45 (34%) met thresholds for substantial benefit using the ESMO-MCBS v1.1 framework. Version 1.1 of the scale facilitated grading of 27 SAT and 1 RCT which were ungradeable with v1.0. Among the 106 studies for which we could calculate scores using both v1.0 and v1.1 of the ESMO-MCBS scale, grades were identical in 96 cases (91%; κ = 0.86). In 10 trials, grades were discrepant, including 5 upgrades and 5 downgrades. We observed only one case of change in substantial benefit thresholds (1%; κ = 0.96). Only 2 SAT (7%) met the threshold for substantial clinical benefit using ESMO-MCBS v1.1.

Conclusions

In patients with advanced solid tumors, approximately one third of trials supporting FDA approval meet the threshold for substantial clinical benefit using ESMO-MCBS v1.1. Drug approvals supported by RCT were more likely to result in substantial benefit compared to approvals supported by SAT.

Clinical trial identification

Legal entity responsible for the study

Hospital de la Santa Creu i Sant Pau.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.